Molecular genetic features of neuroblastoma in adolescent
| Autor: | N. A. Andreeva, T. V. Shamanskaya, D. Yu. Kachanov, R. Kh. Abasov, N. V. Gegeliya, A. E. Druy |
|---|---|
| Jazyk: | ruština |
| Rok vydání: | 2024 |
| Předmět: | |
| Zdroj: | Успехи молекулярной онкологии, Vol 11, Iss 2, Pp 106-115 (2024) |
| Druh dokumentu: | article |
| ISSN: | 2313-805X 2413-3787 |
| DOI: | 10.17650/2313-805X-2024-11-2-106-115 |
| Popis: | Aim. To determin the clinical and biological features of neuroblastoma in patients over 10 years old. Materials and methods. Patients with a histologically verified diagnosis of neuroblastoma / ganglioneuroblastoma established over the age of 10 years were retrospectively selected. Molecular genetic tests included fluorescence in situ hybridization (FISH), multiplex ligation-dependent amplification (MLPA) and targeted next generation sequencing of tumor-derived DNA. The described cohort included 11 adolescents with histologically verified neuroblastoma / ganglioneuroblastoma with a median age of 160 months (124–173 months) at diagnosis and 1 patient aged 41 years (clinical data is missing). All adolescents were treated according to the neuroblastoma treatment protocol NB-2004. The median follow-up time for patients (n = 11) was 32 months (8–68 months). Results. MYCN gene amplification was detected by FISH in 17 %; deletion of 1p and 11q – in 20 and 22.2 % of cases, respectively. Deletions of 1p and 3p (80 % cases each), 11q (67 % cases), 4p (56 % cases), and gain 17q (62.5 % cases) were frequently detected in tumors (n = 9) by MLPA. ATRX gene aberrations was found in 91.6 % (11 / 12). In the most cases (10 / 11; 90 %), ATRX gene deletions of varying length were detected. Missense substitutions p.V1678F, p.N2125I and nonsense mutation p.S213* were detected in 3 / 11 (27.3 %) patients. Moreover, in 2 patients, oncogenic nucleotide substitutions were identified in combination with ATRX gene deletion entire and monosomy X. Oncogenic genetic variants in components of the RAS-RAF-MEK (BRAF, NRAS, ALK) and p53 (ATM, TP53) pathways were detected in 58 % (7 / 12) of cases. No adverse events were observed when ALK inhibitors were added to first-line therapy in neuroblastomas harboring activating ALK mutations. Conclusion. The clinical aggressiveness of adolescent / adult NB may be explained by the replicative immortalization of cells through alternative lengthening of telomeres, which is highlighted by ATRX aberrations. Special therapeutic recommendations should be elaborated for the treatment of patients in this age group, where special attention should be paid to the use of molecularly targeted therapy. |
| Databáze: | Directory of Open Access Journals |
| Externí odkaz: |
|